

A Study of AMDX-2011P in Participants With CAA

NCT05709314

Status	RECRUITING
Phase	Phase 2
Sponsor	Amydis Inc.
Enrollment	25 participants

Key Eligibility Criteria

Inclusion (3)

- Diagnosis of hereditary CAA or probable and definite symptomatic or asymptomatic sporadic CAA diagnosed through genetic testing or according to the modified Boston neuroradiological criteria, who had undergone at least one brain magnetic resonance imaging (MRI) prior to entry into study.
- Abnormality consistent with CAA on historical MRI.
- In general good health

Exclusion (4)

- Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol.
- Clinically significant laboratory abnormalities assessed by the investigator.
- Active malignancy and/or history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low-grade cervical intraepithelial neoplasia.
- Prolonged QTcF (>450 ms for males and >470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in the resting ECG, as judged by the investigator.

Locations (1 total)

Associated Retina Consultants, Phoenix, Arizona, United States